Eisele Jeffrey
Insider CIK 1827326 · APLS Exec VP, Program Team Lead
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals, I | S Sale | 2025-01-29 | 2025-01-30 | 278 | $29.52 | $8.2K | 55,312 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2025-01-22 | 2025-01-23 | 1,291 | $30.43 | $39.3K | 55,590 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2025-01-13 | 2025-01-14 | 264 | $28.70 | $7.6K | 56,881 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-12-23 | 2024-12-27 | 63 | $33.09 | $2.1K | 57,145 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-01-30 | 2024-01-31 | 971 | $65.53 | $63.6K | 57,208 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-01-29 | 2024-01-31 | 279 | $64.14 | $17.9K | 58,179 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-01-23 | 2024-01-24 | 7,378 | $63.69 | $469.9K | 58,458 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-01-22 | 2024-01-23 | 1,607 | $65.00 | $104.5K | 65,836 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-01-17 | 2024-01-18 | 5,207 | $65.58 | $341.5K | 67,443 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2024-01-16 | 2024-01-17 | 28,367 | $66.30 | $1.88M | 28,367 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-01-16 | 2024-01-17 | 438 | $66.81 | $29.3K | 72,650 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2024-01-16 | 2024-01-17 | 19,508 | — | $0 | 73,088 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2023-12-27 | 2023-12-28 | 235 | $60.23 | $14.2K | 53,580 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2023-12-26 | 2023-12-28 | 68 | $57.86 | $3.9K | 53,815 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2023-02-23 | 2023-02-27 | 1,646 | $68.76 | $113.2K | 53,883 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2023-02-21 | 2023-02-22 | 14,023 | — | $0 | 14,023 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | F Tax w/h | 2023-02-21 | 2023-02-22 | 825 | $58.50 | $48.3K | 55,529 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2023-02-21 | 2023-02-22 | 9,886 | — | $0 | 56,354 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2023-01-30 | 2023-01-31 | 883 | $52.76 | $46.6K | 46,468 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | F Tax w/h | 2023-01-27 | 2023-01-30 | 367 | $52.77 | $19.4K | 47,351 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2023-01-23 | 2023-01-25 | 4,479 | $51.58 | $231.0K | 47,718 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | F Tax w/h | 2023-01-20 | 2023-01-24 | 2,033 | $52.05 | $105.8K | 52,197 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2023-01-12 | 2023-01-17 | 35,472 | $52.66 | $1.87M | 35,472 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2023-01-12 | 2023-01-17 | 22,580 | — | $0 | 54,230 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | F Tax w/h | 2022-12-22 | 2022-12-23 | 89 | $51.68 | $4.6K | 31,650 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | J Other | 2022-04-25 | 2022-12-23 | 1,250 | — | $0 | 31,739 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | F Tax w/h | 2022-01-28 | 2022-02-01 | 434 | $38.59 | $16.7K | 32,989 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2022-01-21 | 2022-01-25 | 36,951 | — | $0 | 36,951 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2022-01-21 | 2022-01-25 | 26,051 | — | $0 | 33,423 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | F Tax w/h | 2021-12-22 | 2021-12-23 | 89 | $47.82 | $4.3K | 7,372 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2021-03-01 | 2021-03-03 | 7,500 | — | $0 | 7,500 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2021-03-01 | 2021-03-03 | 1,250 | — | $0 | 7,461 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2021-01-28 | 2021-02-01 | 30,000 | — | $0 | 30,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2021-01-28 | 2021-02-01 | 5,000 | — | $0 | 6,211 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2020-12-23 | 2020-12-23 | 1,211 | — | $0 | 1,211 | SEC↗ |